Animal models of cerebral amyloid angiopathy
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cerebral amyloid angiopathy (CAA), due to vascular amyloid β (Aβ) deposition, is a risk factor for intracerebral haemorrhage and dementia. CAA can occur in sporadic or rare hereditary forms, and is almost invariably associated with Alzheimer’s disease (AD). Experimental (animal) models are of great interest in studying mechanisms and potential treatments for CAA. Naturally occurring animal models of CAA exist, including cats, dogs and non-human primates, which can be used for longitudinal studies. However, due to ethical considerations and low throughput of these models, other animal models are more favourable for research. In the past two decades, a variety of transgenic mouse models expressing the human Aβ precursor protein (APP) has been developed. Many of these mouse models develop CAA in addition to senile plaques, whereas some of these models were generated specifically to study CAA. In addition, other animal models make use of a second stimulus, such as hypoperfusion or hyperhomocysteinemia (HHcy), to accelerate CAA. In this manuscript, we provide a comprehensive review of existing animal models for CAA, which can aid in understanding the pathophysiology of CAA and explore the response to potential therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“Although many studies describe only minimal development of CAA in 5xFAD mice (expressing human APP695 with the Swedish, London and Florida (I716V) mutations, as well as the M146L and L286V mutations in human PS1 under control of the mouse Thy1 promoter (150)), some CAA can be detected as early as 3 months of age using…”
BackgroundAlzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 1×
“6 PDAPP mice PDAPP mice overexpress (18-fold) human APP770 with the V717F Indiana mutation under control of the platelet-derived growth factor (PDGF)-β (120).”
BackgroundThe glymphatic system: a beginner's guide
Jessen, N. A., Munk, A. S. F., Lundgaard, I., & Nedergaard, M. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1581-6 · Cited by 2,075 · cited 1×
“It is believed that the accumulation of Aβ in the vasculature might be caused by impairment of the glymphatic system, and in turn, that accumulation of Aβ might further impair the glymphatic mechanisms (193).”
BackgroundThe toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
Impairment of paravascular clearance pathways in the aging brain
Kress, B. T., Iliff, J. J., Xia, M., Wang, M., Wei, H. S., Zeppenfeld, D., Xie, L., Kang, H., Xu, Q., Liew, J. A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24271 · Cited by 1,521 · cited 1×
“Aged mice have reduced clearance of Aβ along paravascular pathways compared to young mice (192).”
BackgroundTwo amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507 · cited 1×
“4 APP23 APP23 mice overexpress (7-fold) human APP751 with the Swedish double mutation (K670N/M671L) under control of the neuron-specific mouse Thy-1 gene promoter (104-106).”
BackgroundSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
O'Brien, J. T., Erkinjuntti, T., Reisberg, B., Roman, G., Sawada, T., Pantoni, L., Bowler, J. V., Ballard, C., DeCarli, C., Gorelick, P. B., et al. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00305-3 · Cited by 1,139
Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria
Knudsen, K. A., Rosand, J., Karluk, D., & Greenberg, S. M. (2001) · Neurology · doi:10.1212/wnl.56.4.537 · Cited by 1,015 · cited 2×
“3 Aims of this review Definite CAA can only be diagnosed by post-mortem neuropathological evaluation (24).”
BackgroundChishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955 · cited 1×
“TgCRND8 mice express the Swedish double mutation and the Indiana mutation of human APP695 under the control of the Syrian hamster PrP gene promotor, resulting in ± 5-fold higher expression of APP (138).”
BackgroundPrevalence of superficial siderosis in patients with cerebral amyloid angiopathy
Linn, J., Halpin, A., Demaerel, P., Ruhland, J., Giese, A. D., Dichgans, M., van Buchem, M. A., Bruckmann, H., & Greenberg, S. M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dad605 · Cited by 914
Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics
de la Torre, J. C. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00683-0 · Cited by 834
Rennels, M. L., Gregory, T. F., Blaumanis, O. R., Fujimoto, K., & Grady, P. A. (1985) · Brain Research · doi:10.1016/0006-8993(85)91383-6 · Cited by 752 · cited 1×
“The concept of paravascular fluid circulation was first described in 1985 (190), and more recently,”
BackgroundCharacterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.017 · Cited by 744 · cited 2×
“Aβ42 in this model, whereas levels of the vasculotropic Aβ40 are relatively low (145).”
BackgroundResultMoechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V. D., Checler, F., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6483 · Cited by 668
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637 · cited 1×
“BRI-Aβ42 mice develop parenchymal and vascular plaques, whereas BRI-Aβ40 mice do not (158).”
BackgroundGrabowski, T. J., Cho, H. S., Vonsattel, J. P. G., Rebeck, G. W., & Greenberg, S. M. (2001) · Annals of Neurology · doi:10.1002/ana.1009 · Cited by 523
Vinters, H. V., & Gilbert, J. J. (1983) · Stroke · doi:10.1161/01.str.14.6.924 · Cited by 504
Two Types of Sporadic Cerebral Amyloid Angiopathy
Thal, D. R., Ghebremedhin, E., Rüb, U., Yamaguchi, H., Del Tredici, K., & Braak, H. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.282 · Cited by 446
Calhoun, M. E., Burgermeister, P., Phinney, A. L., Stalder, M., Tolnay, M., Wiederhold, K.-H., Abramowski, D., Sturchler-Pierrat, C., Sommer, B., Staufenbiel, M., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14088 · Cited by 410 · cited 6×
“consequence, vessels walls are weakening, leading to aneurysm-like vasodilatation (108), which results in cerebral microhemorrhages in older APP23 animals (104, 108).”
BackgroundInfluentialHawkes, C. A., & McLaurin, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805453106 · Cited by 397
Herzig, M. C., Winkler, D. T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S. D., Danner, S., Abramowski, D., Stürchler-Pierrat, C., Bürki, K., et al. (2004) · Nature Neuroscience · doi:10.1038/nn1302 · Cited by 391 · cited 5×
“approximately 22-25 months of age, first in leptomeningeal vessels, followed by cortical vessels, with an earlier onset for female mice (83).”
BackgroundInfluentialCharidimou, A., Linn, J., Vernooij, M. W., Opherk, C., Akoudad, S., Baron, J.-C., Greenberg, S. M., Jäger, H. R., & Werring, D. J. (2015) · Brain · doi:10.1093/brain/awv162 · Cited by 385
Self-citationCerebral amyloid angiopathy pathology and cognitive domains in older persons
Arvanitakis, Z., Leurgans, S. E., Wang, Z., Wilson, R. S., Bennett, D. A., & Schneider, J. A. (2011) · Annals of Neurology · doi:10.1002/ana.22112 · Cited by 383 · cited 1×
“CAA often occurs sporadically, being observed in 30% of non-demented elderly individuals and in >80% of all patients with Alzheimer’s disease (AD) (4, 5).”
BackgroundDavis, J., Xu, F., Deane, R., Romanov, G., Previti, M. L., Zeigler, K., Zlokovic, B. V., & Van Nostrand, W. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312946200 · Cited by 373 · cited 8×
“Already at 3 months of age, amyloid levels in the thalamic and subicular microvasculature are higher compared with the rest of the forebrain (86).”
BackgroundResultInfluentialRacke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320 · cited 1×
“Like in other transgenic mice models for CAA, the Aβ40:Aβ42 ratio in PDAPP mice is increased in the cerebral vasculature compared to the whole brain (121, 125).”
BackgroundMechanisms to explain the reverse perivascular transport of solutes out of the brain
Schley, D., Carare-Nnadi, R., Please, C. P., Perry, V. H., & Weller, R. O. (2006) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.07.005 · Cited by 293
Fryer, J. D., Simmons, K., Parsadanian, M., Bales, K. R., Paul, S. M., Sullivan, P. M., & Holtzman, D. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5170-04.2005 · Cited by 278 · cited 1×
“Aβ40:Aβ42 ratio caused by APOE ε4 knock-in (136).”
Lord, A., Kalimo, H., Eckman, C., Zhang, X.-Q., Lannfelt, L., & Nilsson, L. N. G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.12.007 · Cited by 260
Intracellular Aβ and cognitive deficits precede β-amyloid deposition in transgenic arcAβ mice
Knobloch, M., Konietzko, U., Krebs, D. C., & Nitsch, R. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.019 · Cited by 259
Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts
Okamoto, Y., Yamamoto, T., Kalaria, R. N., Senzaki, H., Maki, T., Hase, Y., Kitamura, A., Washida, K., Yamada, M., Ito, H., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0925-9 · Cited by 249 · cited 1×
“A study that used microcoils to induce BCAS in Tg-SwDI mice shows that as a result, cerebral blood flow is reduced by 26% and leptomeningeal Aβ accumulation is increased (162).”
BackgroundSporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms
Attems, J. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1074-9 · Cited by 242 · cited 5×
“The most prevalent form of CAA involves the accumulation of the amyloid β protein (Aβ) (2, 3).”
BackgroundInfluentialLemere, C. A., Beierschmitt, A., Iglesias, M., Spooner, E. T., Bloom, J. K., Leverone, J. F., Zheng, J. B., Seabrook, T. J., Louard, D., Li, D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63296-8 · Cited by 230
Merlini, M., Meyer, E. P., Ulmann-Schuler, A., & Nitsch, R. M. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0834-y · Cited by 225
Harigaya, Y., Saido, T. C., Eckman, C. B., Prada, C.-M., Shoji, M., & Younkin, S. G. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3490 · Cited by 202
Attems, J., Jellinger, K. A., & Lintner, F. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1064-y · Cited by 188
Cerebrovascular lesions induce transient -amyloid deposition
Garcia-Alloza, M., Gregory, J., Kuchibhotla, K. V., Fine, S., Wei, Y., Ayata, C., Frosch, M. P., Greenberg, S. M., & Bacskai, B. J. (2011) · Brain · doi:10.1093/brain/awr300 · Cited by 187
Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease.
Gearing, M., Rebeck, G. W., Hyman, B. T., Tigges, J., & Mirra, S. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9382 · Cited by 179 · cited 1×
“These Aβ-containing vessels are also immunopositive for apoE (36).”
BackgroundNonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy
Heuer, E., F. Rosen, R., Cintron, A., & C. Walker, L. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315885 · Cited by 169
Endothelial nitric oxide deficiency promotes Alzheimer’s disease pathology
Austin, S. A., Santhanam, A. V., Hinton, D. J., Choi, D., & Katusic, Z. S. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12334 · Cited by 155 · cited 1×
“2 NOS2 deficiency Nitric oxide synthase 2 (NOS2) plays a role in vascular functioning and is involved in Aβ production (172).”
BackgroundHan, B. H., Zhou, M.-L., Abousaleh, F., Brendza, R. P., Dietrich, H. H., Koenigsknecht-Talboo, J., Cirrito, J. R., Milner, E., Holtzman, D. M., & Zipfel, G. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4686-08.2008 · Cited by 138 · cited 2×
“16 age-dependent impairment of vasomotor function (131, 133, 134).”
BackgroundResultThal, D. R., Capetillo-Zarate, E., Larionov, S., Staufenbiel, M., Zurbruegg, S., & Beckmann, N. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.01.017 · Cited by 138 · cited 7×
“A diagnosis of probable CAA during life is established using clinical data, neuroimaging markers including cerebral microbleeds on T2*-weighted magnetic resonance imaging (MRI) and, if available, histopathological findings (24, 25).”
BackgroundInfluentialNeuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis
Boche, D., Denham, N., Holmes, C., & Nicoll, J. A. R. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0719-5 · Cited by 135 · cited 1×
“clinical trials seem likely to be due largely to these changes in CAA (196, 197).”
BackgroundSelf-citationImmunotherapy Reduces Vascular Amyloid- in PDAPP Mice
Schroeter, S., Khan, K., Barbour, R., Doan, M., Chen, M., Guido, T., Gill, D., Basi, G., Schenk, D., Seubert, P., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2377-07.2008 · Cited by 133
β-Amyloid (Aβ) Deposition in the Brains of Aged Orangutans
Gearing, M., Tigges, J., Mori, H., & Mirra, S. S. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00012-2 · Cited by 130
Sex dimorphism profile of Alzheimer’s disease-type pathologies in an APP/PS1 mouse model
Jiao, S.-S., Bu, X.-L., Liu, Y.-H., Zhu, C., Wang, Q.-H., Shen, L.-L., Liu, C.-H., Wang, Y.-R., Yao, X.-Q., & Wang, Y.-J. (2016) · Neurotoxicity Research · doi:10.1007/s12640-015-9589-x · Cited by 129
Amyloid in the brains of aged squirrel monkeys
Walker, L. C., Masters, C., Beyreuther, K., & Price, D. L. (1990) · Acta Neuropathologica · doi:10.1007/bf00307691 · Cited by 119
Kuo, Y.-M., Beach, T. G., Sue, L. I., Scott, S., Layne, K. J., Kokjohn, T. A., Kalback, W. M., Luehrs, D. C., Vishnivetskaya, T. A., Abramowski, D., et al. (2001) · Molecular Medicine · doi:10.1007/bf03401867 · Cited by 90 · cited 2×
“In addition to plaques, which start to deposit at 6 months of age, these mice develop CAA in leptomeningeal, cortical and hippocampal vessels in an age-dependent matter, with an onset around 9 to 12 months of age (104, 106, 107).”
BackgroundResultLi, H., Guo, Q., Inoue, T., Polito, V. A., Tabuchi, K., Hammer, R. E., Pautler, R. G., Taffet, G. E., & Zheng, H. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-28 · Cited by 86 · cited 2×
“In the APP-DSL model, TAC reduces cerebral blood flow and results in an exacerbation of CAA pathology (153, 164)”
BackgroundMethodKlohs, J., Deistung, A., Schweser, F., Grandjean, J., Dominietto, M., Waschkies, C., Nitsch, R. M., Knuesel, I., Reichenbach, J. R., & Rudin, M. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.118 · Cited by 83
Nochlin, D., Bird, T. D., Nemens, E. J., Ball, M. J., & Sumi, S. M. (1998) · Annals of Neurology · doi:10.1002/ana.410430124 · Cited by 75
Dermaut, B. (2001) · Brain · doi:10.1093/brain/124.12.2383 · Cited by 74
Klohs, J., Baltes, C., Princz-Kranz, F., Ratering, D., Nitsch, R. M., Knuesel, I., & Rudin, M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5626-11.2012 · Cited by 73
Cerebral amyloid angiopathy and plaques, and visceral amyloidosis in aged macaques
Uno, H., Alsum, P. B., Dong, S., Richardson, R., Zimbric, M. L., Thieme, C. S., & Houser†, W. D. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02063-2 · Cited by 72
Cholinergic deafferentation of the rabbit cortex: a new animal model of Aβ deposition
Beach, T. G., Potter, P. E., Kuo, Y.-M., Emmerling, M. R., Durham, R. A., Webster, S. D., Walker, D. G., Sue, L. I., Scott, S., Layne, K. J., et al. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00916-2 · Cited by 71 · cited 2×
“In these rabbits, Aβ can be found at the basal lamina of the vasculature, both in larger arteries and capillaries (183).”
BackgroundBales, K. R., O’Neill, S. M., Pozdnyakov, N., Pan, F., Caouette, D., Pi, Y., Wood, K. M., Volfson, D., Cirrito, J. R., Han, B.-H., et al. (2016) · Brain · doi:10.1093/brain/awv313 · Cited by 68 · cited 1×
“Because of the limitations in our ability to study these factors directly in human tissue, experimental models are very important in attempting to understand these therapy-related side effects, in addition to the potential to treat CAA itself by such approaches (83, 124, 198).”
BackgroundComparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease
Rosen, R. F., Tomidokoro, Y., Farberg, A. S., Dooyema, J., Ciliax, B., Preuss, T. M., Neubert, T. A., Ghiso, J. A., LeVine, H., & Walker, L. C. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.019 · Cited by 46
Senile Plaques in an Aged Western Lowland Gorilla.
KIMURA, N., NAKAMURA, S., GOTO, N., NARUSHIMA, E., HARA, I., SHICHIRI, S., SAITOU, K., NOSE, M., HAYASHI, T., KAWAMURA, S., et al. (2001) · Experimental Animals · doi:10.1538/expanim.50.77 · Cited by 46
Amyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type
Kamp, J. A., Moursel, L. G., Haan, J., Terwindt, G. M., Lesnik Oberstein, S. A. M. J., van Duinen, S. G., & van Roon-Mom, W. M. C. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0008 · Cited by 36
Chambers, J. K., Kuribayashi, H., Ikeda, S.-I., & Une, Y. (2010) · Amyloid · doi:10.3109/13506129.2010.483119 · Cited by 32
Princz-Kranz, F. L., Mueggler, T., Knobloch, M., Nitsch, R. M., & Rudin, M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.06.002 · Cited by 28 · cited 1×
“reactivity in response to a vasodilatory stimulus is decreased (116).”
Background
Cited by
Vasomotion as a Driving Force for Paravascular Clearance in the Awake Mouse Brain
van Veluw, S. J., Hou, S. S., Calvo-Rodriguez, M., Arbel-Ornath, M., Snyder, A. C., Frosch, M. P., Greenberg, S. M., & Bacskai, B. J. (2020) · Neuron · doi:10.1016/j.neuron.2019.10.033 · Cited by 500
“, 1987) and in Tg mice that overproduce Aβ (Jäkel et al., 2017) are predominantly found in the walls of cortical arterioles and leptomeningeal arteries, Aβ clearance appears likely to occur alongside arteries rather than veins.”
BackgroundCerebrovascular Smooth Muscle Cells as the Drivers of Intramural Periarterial Drainage of the Brain
Aldea, R., Weller, R. O., Wilcock, D. M., Carare, R. O., & Richardson, G. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00001 · Cited by 332
Absence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice
Kiani Shabestari, S., Morabito, S., Danhash, E. P., McQuade, A., Sanchez, J. R., Miyoshi, E., Chadarevian, J. P., Claes, C., Coburn, M. A., Hasselmann, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110961 · Cited by 167
“CAA is associated with increased brain hemorrhages in both humans and mice (Jäkel et al., 2017; Zhang-Nunes et al., 2006), and WGCNA analysis further implicated END dysfunction.”
Patel, A. G., Nehete, P. N., Krivoshik, S. R., Pei, X., Cho, E. L., Nehete, B. P., Ramani, M. D., Shao, Y., Williams, L. E., Wisniewski, T., et al. (2021) · Brain · doi:10.1093/brain/awab129 · Cited by 44
“An important feature of cerebral amyloid-b depositions in squirrel monkeys is their predilection for abundant CAA in addition to some parenchymal amyloid depositions.(39,42,59,85) The major complication in ongoing immunotherapeutic clinical trials is ARIA, which is linked to the presence and degree of CAA.”
BackgroundMarazuela, P., Paez-Montserrat, B., Bonaterra-Pastra, A., Solé, M., & Hernández-Guillamon, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094972 · Cited by 31
“Indeed, in vitro and in vivo studies have also demonstrated that testosterone reduces Aβ deposition in AD models [60,61].”
Background
Metadata
- Authors
- Jäkel, L., Van Nostrand, W. E., Nicoll, J. A. R., Werring, D. J., & Verbeek, M. M.
- Venue
- Clinical Science
- Publisher
- Portland Press Ltd.
- Published
- 2017-09-28
- Volume
- 131
- Issue
- 19
- Pages
- 2469-2488
- ISSN
- 0143-5221 (ISSN-L)
- 1470-8736
- OpenAlex
- W2756783629
- Cited by
- 70
- References
- 64
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.